EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

Carcinogenesis

Volumn 30, Issue 7, 2009, Pages 1155-1160

  Mason, Rebecca A ^a   Morlock, Elaine V ^a   Karagas, Margaret R ^a   Kelsey, Karl T ^b,c   Marsit, Carmen J ^b,c   Schned, Alan R ^a   Andrew, Angeline S ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN POLYMORPHISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 67650447331     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp077     Document Type: Article

References (65)

1. Kirkali,Z. et al. (2005) Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology, 66, 4-34.
2. Kantor,A.F. et al. (1985) Familial and environmental interactions in bladder cancer risk. Int. J. Cancer, 35, 703-706.
3. Garcia-Closas,M. et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366, 649-659.
4. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
5. Kawakami,T. et al. (2004) Inactivation of the hMSH3 mismatch repair gene in bladder cancer. Biochem. Biophys. Res. Commun., 325, 934-942.
6. Garcia-Closas,M. et al. (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet., 3, e29.
7. Pham,D. et al. (2006) Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J. Clin. Oncol., 24 1700-1704.
8. Lin,S.Y. et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol., 3, 802-808.
9. Lemos-Gonzalez,Y. et al. (2007) Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol., 28, 273-279.
10. Dominguez-Escrig,J.L. et al. (2004) Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin. Cancer Res., 10, 4874-4884.
11. Smith,K. et al. (1989) Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res., 49, 5810-5815.
12. Neal,D.E. et al. (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65, 1619-1625.
13. Messing,E.M. (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res., 50, 2530-2537.
14. Herbst,R. et al. (1997) SEZ-6: Promoter selectivity, genomic structure and localized expression in the brain. Brain Res. Mol. Brain Res., 44, 309-322.
15. Highshaw,R.A. et al. (2004) Integrating basic science and clinical research in bladder cancer: Update from the first bladder Specialized Program of Research Excellence (SPORE). Curr. Opin. Urol., 14 295-300.
16. Pore,N. et al. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res., 66, 3197-3204.
17. Guerin,M. et al. (1989) Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int. J. Cancer, 43, 201-208.
18. Araujo,A. et al. (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer - a review of the literature. Oncologist, 12, 201-210.
19. Choi,J.E. et al. (2007) Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: A case-control study. BMC Cancer, 7, 199.
20. Nomura,M. et al. (2007) Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med., 4, e125.
21. Brandt,B. et al. (2004) Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res. 64, 7-12.
22. Zhou,Q. et al. (2006) EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol. Ther., 5 1445-1449.
23. Kang,D. et al. (2005) Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet. Genomics, 15, 343-347.
24. Spano,J.P. et al. (2008) Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit. Rev. Oncol. Hematol., 66, 21-30.
25. Spindler,K.L. et al. (2006) Epidermal growth factor receptor analyses in colorectal cancer: A comparison of methods. Int. J. Oncol., 29, 1159-1165.
26. Spindler,K.L. et al. (2006) Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int. J. Radiat. Oncol. Biol. Phys., 66, 500-504.
27. Zhang,W. et al. (2005) Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin. Colorectal Cancer, 5, 124-131.
28. Kimura,T. et al. (2006) Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncol. Rep. 15, 1205-1210.
29. Franco-Hernandez,C. et al. (2007) EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors. Cancer Genet. Cytogenet., 173, 63-67.
30. Wong,K.K. et al. (2006) Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res., 66, 11172-11178.
31. Engelsen,I.B. et al. (2008) HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int. J. Oncol., 32, 307-316.
32. Tovar,V. et al. (2007) [Cell biology and genetics in liver cancer]. Gastroenterol. Hepatol., 30, 360-369.
33. Wang,L. et al. (2002) No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int. J. Cancer, 97, 787-790.
34. Karagas,M.R. et al. (1998) Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ. Health Perspect., 106 (suppl. 4), 1047-1050.
35. Petty,W.J. et al. (2004) Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin. Cancer Res., 10, 7547-7554.
36. Barrett,J.C. et al. (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
37. Ritchie,M.D. et al. (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am. J. Hum. Genet., 69, 138-147.
38. Ritchie,M.D. et al. (2003) Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet. Epidemiol., 24, 150-157.
39. Hahn,L.W. et al. (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics, 19, 376-382.
40. Hahn,L.W. et al. (2004) Ideal discrimination of discrete clinical endpoints using multilocus genotypes. In Silico Biol., 4, 183-194.
41. Coffey,C.S. et al. (2004) An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: The importance of model validation. BMC Bioinformatics, 5, 49-59.
42. Coffey,C.S. et al. (2004) Reporting of model validation procedures in human studies of genetic interactions. Nutrition, 20, 69-73.
43. Wigginton,J.E. et al. (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am. J. Hum. Genet., 76, 887-893.
44. Shigematsu,H. et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst., 97, 339-346.
45. Zhang,G.C. et al. (2007) Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin. Oncol. (R. Coll. Radiol.) 19, 499-506.
46. Schilder,R.J. et al. (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin. Cancer Res., 11, 5539-5548.
47. Dova,L. et al. (2007) Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: To target or not to target? Clin. Exp. Metastasis 24, 79-86.
48. Liu,W. et al. (2003) Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res., 9, 1009-1012.
49. Moriai,T. et al. (1994) A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc. Natl Acad. Sci. USA, 91, 10217-10221.
50. Renner,W. et al. (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res., 37, 443-448.
51. Heist,R.S. et al. (2008) VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J. Clin. Oncol., 26, 856-862.
52. Kim,D.H. et al. (2008) Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br. J. Haematol., 140, 71-79.
53. Streeter,E.H. et al. (2002) Angiogenesis in bladder cancer - prognostic marker and target for future therapy. Surg. Oncol., 11, 85-100.
54. Breunis,W.B. et al. (2006) Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum., 54, 1588-1594.
55. Bates,S. et al. (1995) Cyclin D1 as a cellular proto-oncogene. Semin. Cancer Biol., 6, 73-82.
56. Howe,D. et al. (2001) The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica, 86, 563-569.
57. Wang,S.S. et al. (2006) Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum. Genet., 120, 297-300.
58. Wang,L. et al. (2002) Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis, 23, 257-264.
59. Cortessis,V.K. et al. (2003) A case-control study of cyclinD1 CCND1 870A&rarrG polymorphism and bladder cancer. Carcinogenesis, 24, 1645-1650.
60. Ye,Y. et al. (2008) Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 112, 2467-2474.
61. Shahbazi,M. et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359 397-401.
62. Vishnoi,M. et al. (2008) Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer. Hum. Immunol., 69, 360-367.
63. Araujo,A.P. et al. (2009) Ovarian cancer and genetic susceptibility: Association of A61G polymorphism in the EGF gene. Exp. Biol. Med. (Maywood), 234, 231-235.
64. Jain,M. et al. (2007) Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: An exploratory study in squamous cell esophageal cancer. Cancer Biol. Ther., 6, 1553-1558.
65. Teixeira,A.L. et al. (2008) Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin. Cancer Res., 14, 3367-3371.